Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Edgewise Therapeutics Q3 2026 Results: Turns Profitable, Net Income $1.17B

Edgewise Therapeutics reported 109,482,763 shares of common stock outstanding as of October 31, 2026. The company is focusing its resources on the development of EDG-7500 and EDG-15400 following the Sevasemten Sale, which has impacted its operating expenses and cash position.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax1,321.5-40.7
Net income1,166.2-40.7
EPS (diluted, $ a share)$9.65$-0.39

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: EWTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Edgewise Therapeutics, Inc.: key numbers

Share price
$42.04Close, Nov 17
Market cap
$4.6B
Shares outstanding
109.48MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Edgewise Therapeutics, Inc.

All →
5:22 PM ET Form 4
Insider Selling

Edgewise Therapeutics CFO Michael Nofi Sells $202K of Stock

Michael Nofi, CFO, sold 4,442 shares of Edgewise Therapeutics, Inc. at $45.43 a share, worth $202K in total on Nov 10, 2026. Shares held after the trade: 6,495 (-40.6%).

Value
$202K
Shares
4,442
Price
$45.43
Role
CFO
Holding change
-40.6%
Trade date
Nov 10, 2026
4:02 PM ET 8-K
Financial Results

Edgewise Therapeutics Financial Results

Edgewise Therapeutics reported Q3 2026 financial results, highlighting a $1.348 billion gain from the sale of sevasemten to Servier. The company ended the quarter with $1.74B in cash and is on track to initiate a Phase 3 trial for EDG-7500 in HCM by year-end 2026.

“Our third quarter reflects continued execution across both cardiovascular programs. In HCM, positive CIRRUS-HCM Part D results and our JCI Insight publication reinforce the differentiated profile of EDG-7500, and we expect to initiate our Phase 3 trial by year-end 2026.”

Kevin Koch, Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.